Development and application of peptide-based radiopharmaceuticals

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Chemistry
• Oncology

Background:

• Radiolabeled receptor-binding peptides are a key class of radiopharmaceuticals for tumor diagnosis and therapy.
• The specific receptor binding of ligands is leveraged by labeling them with radionuclides to target tissues expressing particular receptors.
• This concept has driven significant research in nuclear medicine for in vivo targeting of receptor-expressing tissues.

Purpose of the Study:

• To provide an overview of radiolabeled peptides for tumor diagnosis and therapy.
• To discuss criteria for peptide ligand development, radioisotope selection, and labeling methods.
• To review the current clinical applications of radiopeptides in oncology.

Main Methods:

• Review of existing literature on radiolabeled peptides.
• Discussion of peptide ligand design and radioisotope selection criteria.
• Analysis of labeling techniques and chemical synthesis of radiopeptides.

Main Results:

• Peptide-receptor radionuclide imaging (PRRI) uses gamma emitters for visualization.
• Peptide-receptor radionuclide therapy (PRRT) utilizes beta emitters for targeted irradiation.
• Octreotide is a successful example for neuroendocrine tumor imaging and therapy; other peptides are in development.

Conclusions:

• Radiolabeled peptides offer versatile tools for both diagnosing and treating tumors.
• Ongoing research and clinical trials are expanding the utility of various radiopeptides.
• The development of novel radiopeptides holds significant promise for personalized cancer management.